Background and study aim: Colorectal cancer (CRC) is a major cause of cancerrelated deaths in both men and women. Colonoscopy is the most reliable tool for CRC diagnosis, but its complexity and costs hamper its wide application. There is a pressing need for new non-invasive biomarkers to improve early diagnosis of CRC. Aim was to assess serum micro RNA (miR) -21and miR-92a for diagnosis of CRC.
INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer diagnosed in both men and women [1]. The lifetime risk of developing CRC is about 1 in 21 (4.7%) for men and 1 in 23 (4.4%) for women. Many factors increase the risk including: obesity, diet high in red meat (such as beef, pork, lamb, or liver) and processed meat, smoking, heavy alcohol use, history of inflammatory bowel disease, family history of CRC or adenomatous polyps and diabetes mellitus [1].
The CRC mortality rates can be decreased by early diagnosis through screening. However, the present CRC screening techniques [colonoscopy, faecal occult blood test (FOBT), and carcinoembryonic antigen (CEA) test] are limited by their difficulties and costs beside uncertain or delayed results [2] .
Although colonoscopic screening for CRC is the most reliable tool; its difficulties and costs have hampered its wide application. On the other hand, FOBT has the limitation of low sensitivity and dietary restrictions [3]. Thus, there is a pressing need for new noninvasive biomarkers to improve the early detection of CRC [4] .
The discovery of micro RNAs (miRNAs), that play important roles in oncogenesis, has opened new opportunities of non-invasive tests for the early diagnosis of cancers [5] .
MiRNAs are a family of small, noncoding RNAs (19-22 nucleotides) which post-transcriptionally regulate gene expression. In general, miRNAs are transcribed as a group called the pri-miRNA complex, which is cleaved in the nucleus to form the pre-miRNA which is then translocated to the cytoplasm where they undergo final maturation into a functional miRNA [6] . Studies have shown that profiles of miRNA expression differ between normal-and tumour-tissues and vary among different tumour types [7] . Aberrant miRNA expression profiles have been identified and emerged as potential screening biomarkers for CRC [8, 9] .
Although most previous studies on miRNA expression have been performed on tissue specimens, some studies have shown diagnostic and prognostic potential for circulating miRNAs because tumor-derived miRNAs can be present in blood and appear to be stably protected from endogenous ribonuclease activity in the circulation [10].
MiR-21 is an oncogenic miRNA that modulates the expression of multiple cancer-related target genes such as PTEN, TPM1, and PDCD and has been shown to be overexpressed in various human tumors [11] . In addition, miR-21 expression is upregulated in CRC tissues, is elevated during tumor progression, and is also associated with poor survival and response to chemotherapy [12] . Significantly elevated plasma miR-21 expression in CRC was concluded in many studies [11, 13] . On the other hand, MiR92a is part of the miR-17-92 gene cluster located at chromosome 13q13. As a known oncomir, the miR-17-92 cluster can promote cell proliferation, suppress apoptosis of cancer cells, induce tumor angiogenesis and accelerate tumor progression. Elevated expression of miR-92a has been observed in CRC, lung and thyroid cancers suggesting an important role in tumorigenesis. Many studies reported that circulating miR-92 is a potential biomarker for CRC diagnosis [13, 14] . The aim of the present study was to assess miR-21 and miR -92a expression levels as a stable blood-based biomarker for detection of CRC. Pelvi-abdominal ultrasonography and computed tomography (CT scan) were done. Complete colonoscopy was done under sedation with patient preparation through Low-volume Polyethylene glycol-based lavage solution with ascorbic acid (Low-volume PEG-ELS with ascorbic acid) administered as split-dose regimen. Multiple biopsies were taken from any suspected lesion, and were sent for histopathological examination. TNM, Duke's and MAC Coller staging systems were applied.
PATIENTS AND METHODS

Statistical analysis [18] :
The collected data were tabulated and analyzed using SPSS version 16 soft ware (SpssInc, Chicago, ILL Company). Categorical data were presented as number and percentages while quantitative data were expressed as mean ± standard deviation, median and range. Chi square test (X2) or Fisher's exact test (FET) were used to analyze categorical variables. Quantitative data were tested for normality using ShapiroWilks test, assuming normality at P>0.05. Student "t" test was used for normally distributed variables, while Man Whitney U (MWU) test, Kruskal Wallis test and Spearman's correlation coefficient (rho) were used for not normally distributed data. ROC curve was used to determine cutoff values of miRNA-21 and miR-92a with optimum sensitivity and specificity in prediction of patients with CRC. P value ≤ 0.05 was considered significant.
RESULTS
The studied cases included 19 males (56%) and 16 females (44%) with a mean age of 50.6 ± 15.1ys. Age categories among the studied cases showed 26% below 40 years and 63% above 50 years.
The main presenting symptom in the studied cases was bleeding per rectum (15/35 = 42.9%) followed by recent onset constipation (13/35 = 37.1%) and significant weight loss (7/35 = 20%). Positive family history was found in (6/35=17%) of the studied cases.
Colonoscopic examination of the studied cases revealed that the main lesion site of CRC was colon (24/35 = 68.6%), followed by rectum (9/35 = 25.7%) and lastly rectosigmoid (2/35 = 5.7%). Small lesions (<2.5 cm) were seen in 4 cases (11.4%), medium sized ones (2-5 cm) were 37.1% (13 cases), while large lesions were seen in 18 cases (51.4%). Mass was the main lesion seen (94.2%) with only one case showed ulcer and another one showed a stricture. The main histo-pathological CRC types in the studied cases were adenocarcinoma (24/35 = 68.6%) followed by mucinous adenocarcinoma (9/35 = 25.7%) and signet ring cell adenocarcinoma (2/35 = 5.7%).
The majority of the studied cases were Dukes B (88.6%). According to TNM staging, cases with TIIB were (54.3%) followed by TIIA (34.3%). Three cases only were Tis (8.5%). None of the studied cases had nodal involvement or metastases (all were N0M0). At a cut off value ≥5.25 log RU, serum miR-21 was 94.3% sensitive and 93.3% specific for detection of CRC, with AUC = 0.99.At a cut off value ≥6.75 log RU, serum miR-92a was 91.4% sensitive and 80% specific for detection of CRC with AUC = 0.91. When both markers were combined, the sensitivity increased to 97.1% and specifity was 93.3%. Serum miR-92a expression was significantly higher in the cases group compared to the control (7.01 ± 0.234 ≠ 6.56 ± 0.20 log RU) with (P<0.001). told that about half of their studied cases were rectal lesions, this disagreement may be attributed to the large number of their studied cases (400 cases) compared to the small number in our study.
Upon histopathological examination, most of the studied cases in the present study were adenocarcinoma (68.6%). Mucinous and signet ring adenocarcinomas constituted around 25. Our results exhibited significantly higher mean serum miR-21 and miR-92a levels (P<0.001) in the studied cases compared to the control group (5.53 ± 0.17 and 7.01±0.234 ≠ 4.82± 0.20 and 6.56 ± 0.20 log RU, respectively). This was in agreement with, Wang et al. [37] who found that miR-21& miRNA-92a levels were significantly higher in CRC cases and added that miR92a could distinguish CRC and advanced adenoma from normal controls, with a sensitivity of >62% and specificity of >84%. No statistically significant association was found between serum miR-21 or miR-92a level and either age or sex. This comes in agreement with Guang-Hui and colleagues [38] . The mean value of serum miR-92a level showed a statistically significant positive correlation with tumor size (P ˂ 0.003). The mean values in small, medium and large CRC lesions were 6.75, 6.93 and 7.13 log RU, respectively This comes in agreement with Zhou et al. [41] who reported that over expression of miR-92a is correlated with TNM stages and poor prognosis in CRC. Nami and his colleagues [42] told that a significant increase in miR-92a expression was more frequently observed in CRCs than in colorectal adenomas, and suggested that miR-92a could be a potential marker for discrimination between cancers and adenomas and a potential promoter for the phenotypic changes from adenoma into carcinoma. They added that miR-92a expression was related to advanced clinical stages and to the depth of invasion.
The mean value of serum miR-92a level showed a statistically significant positive correlation and different TNM stages (P>0.03). The mean values in Tis-T2, T3 and T4 were 6.67, 7.01 and 7.08 log RU, respectively .This comes in agreement Zhang et al. [43] who reported that expression of miR92a was associated with more advanced tumorlymph node-metastasis (TNM) stage (P=0.07).
When ROC curves were applied; serum miR-21 at a cutoff value of ≥5.25 Log RU was 94.3% sensitive and 93.3% specific for diagnosis of CRC with an AUROC = 0.99. Wang et al. [37] reported that serum miR-21 showed a sensitivity and specificity of 93% and 91%, respectively. While, Ahmed et al. [44] and Schetter et al. [40] reported that serum miR-21 could detect CRC with 90% sensitivity and specificity. On the other hand, Guang-Hui et al. [38] reported that the sensitivity of serum miR-21 for detection CRC was only 65% and the specificity was 85%.
In the present study, serum miR-21 level ≥5.61 Log RU, could significantly discriminate cases of CRC lesions larger than 5 cm with 83.3% sensitivity and 82.4% specificity, with AUROC =0.87 as well as cases with high grade adenocarcinoma with 100% sensitivity and 63.3% specificity and AUROC = 0.85. At a level ≥ 5.43 log RU, miR-21 could significantly detect cases of T stage >2 with 90% sensitivity and 100% specificity, with AUROC = 0.95, and at a level ≥5.6 log RU, it could significantly detect cases of MaCollerB3 with 68.4% sensitivity and 68.8% specificity, with AUROC = 0.71. Serum miR-92a at a cut off value of ≥ 6.75 Log RU, was 91.4% sensitive and 80% specific for diagnosis of CRC with an AUROC = 0.91. Other studies reported plasma miR-92a to have a sensitivity and specificity of 89% and 70% respectively at a cut off value of ≥ 6.75 Log RU in distinguishing CRC patients from healthy controls In addition, many studies have found miR-92a expression to be associated with other diseases such as hepatocellular carcinoma, breast cancer, and even cardiovascular diseases, pointing to the low specificity of miR-92a. MiR-92a which has been studied extensively in plasma has also been observed to have higher expression levels in the stool of CRC patients [13] . However, the sensitivity and specificity of the miRNA 92a for detecting CRC was significantly lower in stool than in plasma [13] .
The present study found that serum miR-92a at a cut off value ≥7.05 log RU, could significantly detect cases of CRC lesions larger than 5 cm with 72.2% sensitivity and 70.6% specificity, with AUROC = 0.82. This was in agreement with Guang et al. [38] who reported that, at a cut off ≥7.0, AUROC value of 0.722 (95% CI = 0.633-0.811) with a sensitivity of 70% and specificity of 70%. At level ≥7.1 log RU, miR-92a could significantly detect cases of MaC CollerB3 with 63.2% sensitivity and 81.8% specificity, with AUROC= 0.76 .This was in agreement with Guang et al. [38] who told that serum levels of miR -92a were potential biomarkers for CRC, and at the cut-off value of ≥7.1, the sensitivity was 65.5% and the specificity was 82.5% with an AUROC = 0.786.
At level ≥6.96 log RU, miR-92a could significantly detect cases of T stage >2 with 77.4% sensitivity and 100% specificity, with AUROC= 0.9 This was in agreement with Guang et al. [38] .
When serum miR-21 (≥5.25 log RU) and miR92a (≥6.75 log RU) were combined together, the sensitivity for detection of CRC was increased to 97.1% and the specificity was 93.3%.
In conclusion, serum miR-21 and miR-92a expression levels represent a sensitive and specific tool for detection of CRC with higher accuracy of miR-21.
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